Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

Even initial stages of chronic kidney disease in patients with ANCA-associated vasculitis increase the risk for end-stage kidney disease. Even mild kidney impairment in patients with ANCA-associated ...

“ANCA-associated vasculitis is associated with increased early mortality and a high risk of end-stage renal disease,” Peter A. Merkel, MD, MPH, chief of rheumatology and a professor of medicine and ...

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish ...

ATS 2022, San Francisco, CA – Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated ...

ST. GALLEN, Switzerland & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ:CCXI) today announced positive ...

DelveInsight's“ ANCA Vasculitis Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA ...

An investigational C5a receptor inhibitor, avacopan, was effective as a steroid-sparing induction treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a phase III trial ...

Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy MOUNTAIN VIEW, Calif., June 03, 2020 ...

-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- “The vasculitis community is elated that TAVNEOS is now approved, bringing a much-needed new treatment option to ...